^
Association details:
| Biomarker: | TBX21 overexpression |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single-Cell Immune Profiling Patients (Pts) With Relapsed/Refractory (R/R) B-Cell Malignancies (BCM) Treated With Ibrutinib (Ibr) + Nivolumab (Nivo)
Published date:
05/15/2020
Excerpt:
Ibr (oral 420 or 560 mg/day) + nivo (IV 3 mg/kg, 14-day cycle) showed activity and safety in pts with R/R B-NHL...Peripheral blood mononuclear cell samples from 58 pts were analyzed by mass cytometry (HeliosTM) at baseline, early (Cycle 3 Day 1) and late (Cycle 5/Cycle 13 Day 1) treatment, and end of treatment for immune profiling....A large increase in Tbet expression (known to have cytolytic function) at early treatment vs baseline in a CD8+ EM T cell subset was related to longer progression-free survival in FL.
